Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Gesynta Pharma’s GS-248 Wins FDA Orphan Drug Designation

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Gesynta Pharma’s GS-248, its oral therapy for people with systemic sclerosis (scleroderma). Orphan drug status aims to encourage therapies for rare diseases through benefits such as seven years of market exclusivity and exemption from FDA fees. “The…

CD146 Protein May Help Identify, Treat SSc

High levels of a form of the CD146 protein, normally found on endothelial cells — those that line blood vessel walls — may be a potential biomarker in identifying people with systemic sclerosis (SSc), a study suggests. Certain forms of the protein are implicated in lung scarring (pulmonary fibrosis)…

Low Oxygen in Muscles Linked to Poor Exercise Capacity in SSc Patients

Poor oxygenation in skeletal muscles — those used in voluntary movements — contributes to impaired exercise capacity in people with scleroderma, a study suggests. The study, “Reduced exercise capacity in patients with systemic sclerosis is associated with lower peak tissue oxygen extraction: a cardiovascular magnetic resonance-augmented cardiopulmonary exercise…

Study: Fecal Microbiome More Diverse in SSc Patients

The fecal microbiome — the community of microbes present in stools — of scleroderma patients is more diverse than that of healthy people, according to a Canadian study. The findings also showed that the diversity and abundance of bacterial species in the stools was higher among patients with an abnormal…